Idelalisib-Rituximab Combo Found Active in R/R CLL Regardless of Complex Karyotype
Presence of a complex karyotype did not affect progression-free or overall survival.
Hematologic Cancers
Prevalence of Hypertension Higher With Myeloproliferative Neoplasms Than in General Population
In this prospective study, researchers investigated the incidence of pulmonary hypertension among patients with MPNs. Their results led them to recommend systematic screening in this patient population.
Nelfinavir Plus Lenalidomide, Dexamethasone Improves Response in Lenalidomide-Refractory Multiple Myeloma
Results of a phase 1/2 trial demonstrated the efficacy of nelfinavir in combination with lenalidomide and dexamethasone for lenalidomide-refractory MM.
Analysis of Cardiovascular Disease Risks With Different Types of Cancer
Population-based cohort study demonstrated associations between many site-specific cancers and the development of CVDs.
Germline BRCA2 Mutations Linked to Pediatric Lymphomas
Survivors of NHL should be offered genetic counseling.
A Tool to Select Candidates for Allogeneic Hematopoietic Cell Transplant in CLL
As oncologists welcome new chronic lymphocytic leukemia treatments, one researcher creates a scoring system to make the case for transplants.
Biological Differences Between 2 Rare Leukemias Do Not Influence Clinical Outcomes
The classification of acute leukemia according to WHO criteria as undifferentiated or minimally differentiated did not appear to have an effect on overall outcomes.
MGUS: Risk of Progression to Multiple Myeloma Can Change Over Time
A risk signature is not constant in a given patient over time—it is subject to change depending on a variety of factors.
Some Discrepancies Seen Between Real-Life and Guideline-Recommended Care of Chronic Myeloid Leukemia
An assessment of a population of patients with CML revealed that some are not receiving guideline-based treatment, including TKIs.
10-Year OS After Bone Marrow Transplantation for CML Similar With/Without Prior TKI Therapy
Researchers sought to determine whether late mortality rates are affected by exposure to a BCR-ABL TKI prior to BMT in patients with CML who survive at least 2 years posttransplantation.
Next post in Chronic Myeloid Leukemia
